search

Innate Pharma (IPHA)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Innate Pharma PACIFIC-9 Trial Data Delayed to 2027
Oct 27, 2026

Innate Pharma PACIFIC-9 Trial Data Delayed to 2027

Innate Pharma (NASDAQ:IPHA) announced a delay in the high-level data readout for its PACIFIC-9 Phase 3 trial to the first half of 2027. This revision by AstraZeneca (NYSE:AZN) is due to the event-driven design of the clinical study, which evaluates durvalumab combined with monalizumab or oleclumab for unresectable Stage III non-small cell lung cancer. The trial's enrollment is complete, and monalizumab is an anti-NKG2A antibody co-developed by Innate Pharma and AstraZeneca.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Bearish